Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed written consent~* Clinical diagnosis of type 2 diabetes mellitus for at least 6 months prior to screening~* Glycosylated hemoglobin (HbA1c) level of 7.6 to 12.0 % at screening (both values inclusive)~* Body mass index (BMI) of 18.0 to 35 kg/m2 at screening (both values inclusive)~* Stable doses OADs for at least 3 months prior to treatment of experimental drug~* Female patients of childbearing potential who are willing to use two acceptable methods of contraception, (e.g., intra-uterine device plus condom, spermicidal gel plus condom, diaphragm plus condom, etc.), from the time of screening and for the duration of the trial, through trial completion~Exclusion Criteria:~* Acute inflammation disease for 3 weeks prior to screening~* Deviation of the laboratory results conducted during the screening:~Hemoglobin value \< 9,0 g/dl; Hematocrit value \< 30 %; ALT and AST value \> 2 folds as high as maximal normal value; Serum bilirubin value \> 1.5 folds as high as maximal normal value~* History of hematological disorders that can affect the reliability of HbA1c estimation (hemoglobinopathies, hemolytic anemia, etc.)~* Serious blood loss for 3 months prior to screening (blood donation, surgery procedure, etc.)~* Contraindication to the use of insulin Lispro Biphasic 25~* Insulin resistance over 1.5 U/kg insulin pro day~* Presence of insulin antibodies in the blood at the screening ˃10 U/ml~* Use of 3 or more oral antidiabetic drugs (OAD)~* Presence of severe diabetes complications~* History or presence of uncontrolled diabetes mellitus for 6 months prior to screening~* Deviation of vital signs, which can influence to results~* History of administration of glucocorticoids for 1 year prior to screening~* History of autoimmune disease, except controlled autoimmune thyroid disease~* Pregnant and breast-feeding women~* History of hypersensitivity to any of the active or inactive ingredients of the insulin/insulin analogue preparations used in the trial, OR history of significant allergic drug reactions~* Administration of any immunosuppressive drugs (Cyclosporinum, Methotrexatum)~* Incomplete recovery after surgery procedure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Humalog® Mix 25 (Type: ACTIVE_COMPARATOR): Insulin Humalog® Mix 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement
- Insulin Lispro Biphasic 25 (Type: EXPERIMENTAL): Insulin Lispro Biphasic 25 twice daily, individually glucose-level based administered doses +/- 1 or 2 OADs in stable doses, started before enrollement

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete